1. Creatine Monohydrate, Comprehensive Profile
S. Singh and A. Dash
2. Cytarabine, Comprehensive Profile
H. El-Subbagh and A. Al-Badr
3. Famotidine, Analytical Profile
M. Al-Omara and A. Al-Mohizea
4. Fexofenadine Hydrochloride, Comprehensive Profile
L. Kumar, S. Alam, C. Lal Meena, R. Jain, and A. Bansal
5. Itraconazole, Comprehensive Profile
A. Al-Badr and H. El-Subbagh
6. Ofloxacin, Comprehensive Profile
M. Al-Omar
7. Paclitaxel, Comprehensive Profile
S. Jauhari, S. Singh, and A. Dash
Dr. Brittain is presently the Institute Director of the Center for
Pharmaceutical Physics, a research and consulting institute he
established in 1999 for the study of substances having
pharmaceutical interest. His research interest include all areas of
pharmaceutical physics and physical pharmacy, including
preformulation, formulation design, product characterization,
polymorphism, solvatomorphism, and cocrystals of drug substances.
Formerly, Dr. Brittain was Vice President for Pharmaceutical
Development of Discovery Laboratories, Inc., he served as Director
of Pharmaceutical Development at Ohmeda, Inc., and also led a
variety of groups within the Analytical R&D department at
Bristol-Myers Squibb.
Dr. Brittain is a graduate of Queens College (B.A. in chemistry,
1970; M.A. in physical chemistry 1972), and of the City University
of New York (Ph.D. in physical chemistry, 1975). He was a
postdoctoral fellow at the University of Virginia, and has held
full-time faculty positions at Ferrum College (Assistant Professor
of Chemistry) and Seton Hall University (Associate Professor of
Physical and Inorganic Chemistry). He has been Adjunct Professor of
Pharmaceutics at Rutgers University, and both Adjunct Professor of
Chemistry and Visiting Research Scientist at Lehigh University.
Dr. Brittain has authored over 340 research publications and book
chapters, and has presented over 175 invited lectures and short
courses in the pharmaceutical field. He has edited the monographs
Analytical Applications of Circular Dichroism, Physical
Characterization of Pharmaceutical Solids, Polymorphism in
Pharmaceutical Solids (first and second editions), Spectroscopy of
Pharmaceutical Solids, and Preformulation in Solid Dosage Form
Development. He is also the Editor-In-Chief of the book series
Profiles of Drug Substances, Excipients, and Related Methodology,
having edited 23 published volumes in the series that is now
published annually by Elsevier. Dr. Brittain is also an Editor of
Physical Pharmacy for the Journal of Pharmaceutical Sciences, and
is a co-author of 22 issued United States patents.
During his academic tenure at Seton Hall University, in 1980 Dr.
Brittain was named as one of the Teacher-Scholars of the Camille
and Henry Dreyfus Foundation. Dr. Brittain was elected as a Fellow
of the American Association of Pharmaceutical Sciences (AAPS) in
1991, and received the AAPS Research Achievement Award in Analysis
and Pharmaceutical Quality in 1998. He is also a Fellow of the
Royal Society of Chemistry.
 |
Ask a Question About this Product More... |
|
